What strategies would be helpful in further improving transfusion safety?;Quelles sont aujourd'hui les nouvelles strategies susceptibles de faire progresser la securite transfusionnelle en France?

Annales de Medecine Interne

Volumn 150, Issue 8, 1999, Pages 623-630

  Hervé, Patrick ^a   Lapierre, Valérie ^b   Morel, Pascal ^a   Tiberghien, Pierre ^a  

^a ETS de Franche Comte   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biotechnology; Blood substitutes; Transfusion safety

Indexed keywords

BLOOD DONOR; BLOOD TRANSFUSION; FRANCE; GOOD CLINICAL PRACTICE; HUMAN; PATIENT ATTITUDE; QUALITY CONTROL; REVIEW;

BIOTECHNOLOGY; BLOOD COMPONENT TRANSFUSION; BLOOD DONORS; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; FRANCE; HUMANS; PLATELET TRANSFUSION; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; RESEARCH; RISK FACTORS; SAFETY;

EID: 0033386375     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. MORELLE A : La défaite de la santé publique. Paris : Flammarion, 1996 ; 389.
2. MOREL P, HERVÉ P: Surveillance of blood transfusion safety: contribution of the hemovigilance strategy in France. Transf Med Rev, 1998; 12: 109-27.
3. PEREZ P, NGOMBET N, DEBEIR J, et al. : Les incidents transfusionnels par contamination bactérienne : synthèse de la littérature et des données d'hémovigilance. Transf Clin Biol, 1998; 5 : 203-10.
4. LAPIERRE V, AUPERIN A, TIBERGHIEN P: Transfusion-induced imunomodulation following cancer surgery: fact or fiction? J Natl Cancer Inst, 1998; 90: 573-80.
5. MIYAKAWA Y, MAYUMI M: Hepatitis G virus: a true hepatitis virus or an accidental tourist? N Engl J Med, 1997; 336: 795-6.
6. SIMMONDS P, DAVIDSON F, LYCETT C, et al.: Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet, 1998; 352: 191-5.
7. BROWN P: Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Haematol, 1995; 2: 472-7.
8. KLEIN MA, FRIGG R, FLECHSIG E, et al.: A crutial rôle for B cells in neuro-invasive therapy. Nature, 1997; 390: 687-90.
9. HERVÉ P, SALMI R : L'hémovigilance : un objectif au service de la médecine transfusionnelle. Cah Anesthesiol, 1994 ; 3 : 367-73.
10. BLAJCHMAN MA: Transfusion-associated bacterial sepsis: the phoenix rises yet again. Transfusion, 1994; 34: 940-2.
11. MOREL P, MASSE M, TALON D, LEPRAT R: Systematic microbiological control of platelet concentrates (PC) using an automated culture system: analysis of 5015 results. Transfusion, 1997; 9 (suppl): 56S.
12. MOREL P, BARDIAUX L, POUTHIER F, HERVÉ P: Éviction des donneurs transfusés : conséquences en Franche-Comté. Propositions d'accompagnement de la mesure. Gazette Transf, 1997 ; 134 : 3-11.
13. LEFRERE JJ : Le renforcement de la sécurité transfusionnelle des produits sanguins labiles par le dépistage des génomes viraux dans les dons du sang. Hematologie, 1998 ; 4 : 116-24.
14. NÜBLING CM, SEITZ R, LÖWER J: Application of nucleic acid amplification techniques for blood donation screening. Infusion Ther Transf Med, 1998; 25: 86-90.
15. CARDOSO MS, KOERNER K, KUBANEK B: Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus and HIV: preliminary results. Transfusion, 1998; 38: 905-7.
16. BURNOUF-RADOSEVICH M, BURNOUF T, HUART JJ : Pasteurisation industrielle du plasma et critères de qualité. Rev Fr Transf Hemobiol, 1993 ; 36 : 93-102.
17. CHAPMAN J: Viruses inactivation of plasma by methylene blue photoinactivation: approaches and toxicology. Transfusion Today, 1994; 20: 2-4.
18. HANSON CV: Photochemical inactivation of viruses with psoralens: an overview. Blood Cells, 1992; 18: 7-25.
19. MARGOLIS-NANNO H, ROBINSON R, BEN-HUR E, HOROWITZ B: Quencher-enhanced specificity psoralen-photosensitized virus inactivation in platelet concentrates. Transfusion, 1994; 34: 802-10.
20. SIEBER F, O'BRIEN JM, GAFFNEY DK: Merocyanine-sensitized photoinactivation of envelopped viruses. Blood Cells, 1992; 18: 117-28.
21. GOLDSTEIN J: Conversion of ABO blood groups. Transf Med Rev, 1989; 3: 206-12.
22. LENNY LL, HURST R, GOLDSTEIN J, GALBRAITH RA: Transfusions to group O subjects of 2 units of red cells enzymatically converted from group B to group O. Transfusion, 1994; 34: 309-14.
23. SUGAWARA S, ABO T, KUMAGAL K: A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH3. J Immunol Methods, 1987; 100: 83-90.
24. NOVOTNY VMJ, HUIZINGA TWJ, VAN DOORN R, BRIET E, BRAND A: HLA-class I eluted platelets as alternative to HLA matched platelet transfusion. Transfusion, 1996; 36: 438-44.
25. ANONYMOUS: The trial to reduce alloimmunization to platelets study group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion. N Engl J Med, 1997; 337: 1861-9.
26. RINDER HM, AULT KA: Platelet activation and its detection during the preparation of platelets for transfusion. Transf Med Rev, 1998; 12: 271-87.
27. WINSLOW RM : Les substituts de globules rouges : nouvelles solutions pour de vieux problèmes. Hematologie, 1998 ; 4 : 267-76.
28. WINSLOW RM: Blood substitutes: a moving target. Nature Med, 1995; 1: 1212-5.
29. SIRIEX D, NICOLAS-ROBIN A, BARON JF : Les transporteurs d'oxygène : solution d'hémoglobines et fluorocarbones. STV, 1996 ; 8 : 511-7.
30. PROWSE CV: Alternative to human blood and blood ressources. Vox Sang, 1998; 74 (suppl 2): 21-8.
31. PRZYBELSKI RJ, MALCOLM DS, BURRIS DG, WINSLOW RM: Cross-linked hemoglobin solution as a resuscitative fluid after hemorraghe in the rat. J Lab Clin Med, 1991; 117: 143-51.
32. NELSON D, HAI T, SRNAK A, et al.: Synthesis and properties of polymerized diaspirin cross-linked hemoglobins. Biomat Artif Cells Immobil Biotech, 1992; 20: 253-8.
33. RUDOLPH AS: Encapsulation of hemoglobin in liposomes. In: Winslow RM, Vandegriff KD, Intaglietta M, eds. Blood substitutes: physiological basis of efficacy. Boston: Birkhouser, 1995: 90-104.
34. THEISEN M : Les plantes comme bioréacteurs. Biofutur, 1997 ; 168 : 47-51.
35. ALVING BM, REID TJ, FRATANTONI JC, FINLAYSON JS: Frozen platelets and platelet substitutes in transfusion medicine. Transfusion, 1997; 37: 866-76.
36. CHAO FC, KIM BK, HOURANICH AM, et al.: Infusible platelet membrane microvesicles: a potential transfusion substitue for platelets. Transfusion, 1996; 36: 536-42.
37. READ MS, REDDICK RL, BODE AP, et al.: Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: Potential for long term storage of dried platelets for transfusion. Proc Natl Acad Sci, USA 1995; 92: 397-401.
38. LEE DH, BLAJCHMAN MA: Novel platelet products and substitutes. Transf Med Rev, 1998; 12: 175-87.
39. RYBAK ME, RENZULLI LA: A liposome based platelet substitute, the plateletsome with hemostatic efficacy. Biomat Artif Cells Immobil Biotech, 1993; 21: 101-18.
40. HÖGMAN CF, ERIKSSON L, GONG J, et al.: Half-strength citrated CPD combined with a new additive solution for improve storage of red blood cells suitable for clinical use. Vox Sang, 1993; 65: 271-8.
41. KOERNER K, SAHLMEN P, ZIMMERMANN B, et al.: In vitro platelet function during storage in three different additive solutions. Vox Sang, 1994; 67: 154-9.
42. KLINGER MH, JOSCH M, KLÜTER H: Platelets stored in a glucose-free additive solution or in autologous plasma. An ultrastructural and morphocentric evaluation. Vox Sang, 1996; 71: 13-20.
43. RAMSEY G: Hematopoietic growth factors and transfusion medicine. Transf Med Rev, 1998; 12: 195-205.
44. PAMPHILON DH: The effect of cytokine therapy on transfusion medicine. Transf Sci, 1997; 18: 147-57.
45. GOODNOUGH LT, MONK TG, ANDRIOLE GL: Erythropoietin therapy. N Engl J Med, 1997; 336: 933-8.
46. FANUCCI M, GLASPY J, CRAWFORD J, et al.: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on plateletd counts after chemotherapy for lung cancer. N Engl J Med, 1997; 336: 404-9.
47. ABINA MA, TULLIEZ M, DUFFOUR MT, et al.: Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO. J Immunol, 1998; 160: 4481-9.
48. HARTMANN O, LE CORROLER AG, BLAISE D, et al.: Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. Ann Intern Med, 1997; 126: 600-7.
49. SCHEDING S, KRATZ-ALBERS K, MEISTER B, et al.: Ex vivo expansion of hematopoietic progenitor cells for clinical use. Semin Hematol, 1998; 35: 232-40.
50. AGLIETTA M, BERTOLINI F, CARLO-STELLA C, et al.: Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica, 1998; 83: 824-48.
51. REIFFERS J, CAILLIOT C, DAZEY B, et al.: Infusion of expanded CD34 + selected cells can abrogate post myeloablative chemotherapy neutropenia in patients with hematologic malignancies (abstract). Blood, 1998; 92 (suppl 1): 126a.